SCHEMBL6901895

SCHEMBL6901895

CCCCOc1cn(-c2cccc(-c3ccccc3)c2)c(N)cc1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
COMT P21964 10/20 0.46
TET2 Q6N021 1/20 0.42
TET1 Q8NFU7 1/20 0.42
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
METTL3 Q86U44 1/20 0.38
METTL14 Q9HCE5 1/20 0.38
BCHE P06276 1/20 0.38
ACHE P22303 1/20 0.38
PTPN11 Q06124 1/20 0.37
TLR8 Q9NR97 1/20 0.37
FGFR1 P11362 1/20 0.37
ALDH1A1 P00352 2/20 0.37
FAAH O00519 1/20 0.37
HSP90AA1 P07900 1/20 0.37
PKM P14618 1/20 0.37
HTT P42858 1/20 0.37
ATM Q13315 1/20 0.37
MGLL Q99685 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6901759 0.87 COMT (0.60) COMTMETTL3METTL14PTPN11FAAH
SCHEMBL6900184 0.84 COMT (0.63) COMTMETTL3METTL14PTPN11
SCHEMBL6899328 0.84 COMT (0.44) COMTTET2TET1METTL3METTL14
SCHEMBL2464003 0.83 COMT (0.44) COMTTET2TET1
SCHEMBL6900917 0.80 COMT (0.55) COMTPTPN11ALDH1A1FAAHHSP90AA1
SCHEMBL6899338 0.76 CNR2 (0.48) COMTMETTL3METTL14ALDH1A1ATM
SCHEMBL6900023 0.76 COMT (0.40) COMTMETTL3METTL14PTPN11
SCHEMBL2432898 0.74 COMT (0.74) COMTTET2TET1
SCHEMBL2467412 0.71 COMT (0.61) COMTL3MBTL1
SCHEMBL10445693 0.70 MEN1 (0.44) PTPN11FGFR1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9399651-B2 Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders Merck, Sharp & Dohme Corp. (US) 2016-07-26 US disclosed
US-20150299227-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS MERCK SHARP & DOHME CORP. (US) 2015-10-22 US disclosed
US-9024032-B2 Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders MERCK SHARP & DOHME CORP. (US) 2015-05-05 US disclosed
US-20130084346-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS MERCK SHARP & DOHME LLC 2013-04-04 US disclosed
WO-2011109254-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS MERCK SHARP & DOHME CORP. (US) 2011-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299227-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS COMT, PNMT, TPMT COMT 1/4885TET2 42/4885TET1 36/4885
US-20130084346-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS COMT, PNMT, TPMT COMT 1/4885TET2 42/4885TET1 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.